Traumatic Brain Injury Stem Cell Therapy Development

A Traumatic Brain Injury (TBI) is a complex and often life-altering medical condition that occurs when there is sudden physical trauma to the head, resulting in damage to the brain. Stem cell therapy for TBI involves the use of stem cells to promote tissue repair, reduce inflammation, and enhance the brain's natural healing processes. CD BioSciences offers stem cell therapy development services for TBI, based on out advanced technology and professional team.

Introduction into Traumatic Brain Injury

Traumatic brain injury (TBI) is the leading cause of injury-related death and disability worldwide and is characterized by disruption of the normal physiological functioning of the brain following trauma. It can lead to serious complications, such as physical, cognitive and emotional impairments.

Fig 1. TBI

Common causes of Traumatic Brain Injury (TBI)

Motor vehicle accidents, account for approximately 50% of all TBIs
Fall, accounting for 20-30% of all TBIs
Work related incidents
Sports related injuries
Alcohol

Stem Cell Therapy for Traumatic Brain Injury

Stem cell transplantation has been proven to promoted the improvement of several neurological parameters. Specifically, NSC and MSC (e.g., BM-MSC, AD-MSC, and UC-MSC) are able to regenerate damaged neural tissue.

NSCs are a type of cell capable of self-renewal, they can differentiate into neurons, oligodendrocytes, and astrocytes. Additionally, NSCs are able to release cytokines and neurotrophic factors such as brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF), and insulin growth-factors-1 (IGF-1). MSCs are able to selectively migrate to damaged neural tissue in TBI rats and then differentiate into neurons and astrocytes to repair the damaged areas, thereby enhancing motor activity after TBI.

Clinical trials of stem cell therapy in TBI
(Condition - Primary Outcome)

Patients with mild TBI or concussion syndrome at least 1 months - The safety of AD-cSVF in patients with TBI and concussion syndrome will be assessed by measuring the side events at baseline and 6 months. Moreover, it will be assessed the clinical symptoms associated with TBI and concussion such as recurrent headaches, amnesia, behavioral change, cognitive impairment, as well as sleep disturbances.
Patients with neurological injury at least 6 months - Will be evaluated the safety of autologous AD-MSCs transplantation in brain regions associated with specific neurocognitive deficits of patients with both subacute and chronic neurological injury
Patients with motor deficits from TBI at least 12 months - It has been assessed the motor functions in patients with chronic TBI after stereotactic intracranial implantation of allogeneic SB623
Patients with TBI within 24 h after injury - Will be evaluated both the macrostructural and microstructural properties of gray matter, white matter as well as the integrity of the regions in the corpus callosum

Patients with severe TBI within 36 h after injury - It was shown the safety of BMMNCs autologous transplantation after TBI
Patients with TBI within 24 h after lesion - It has been evaluated the safety of BMPCs autologous transplantation
Patients with damage to the central or peripheral nervous system - Will be assessed the efficacy of intravenous and intranasal administration of autologous BM-MSCs by measuring the Activities of Daily Living at 3,6 and 12 months following the procedure
Patients with severe TBI within 24 h after injury - Will be evaluated by using diffusion tensor MRI the conservation of both white and grey matter in the groups of patients treated and untreated after the injury
Patients who present brain death caused by TBI with axonal injury shown by MRI - Will be demonstrated the reversal of brain death documented by clinical examination or electroencephalogram in the 15 days' frame time

Our Services

CD BioSciences offers stem cell therapy development service for spinal cord injury based on our advanced technology and professional team. Our stem cell therapy development services are performed in stem cells included but not limited as follows:

Neural Stem Cells (NSCs)
Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs)

Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)
Induced Pluripotent Stem Cells (iPSCs)

As a pioneer in biotechnology, CD BioSciences has grown into one of the largest independent biotechnology companies in the world. CD BioSciences is committed to providing professional and efficient service to our customers around the world. If you are interested in our service, please contact us.

For research use only, not for clinical use.